Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age

Satellos Bioscience Inc. has completed enrollment for its BASECAMP Phase 2 clinical trial, which is assessing the efficacy of forazapadin in treating Duchenne muscular dystrophy in boys aged 7 to 10. Forazapadin is an oral small molecule drug aimed at enhancing muscle regeneration in patients with DMD and other degenerative muscle diseases.